Abstract: Disclosed is a use of a heterocyclic compound. Specifically disclosed is a use of a heterocyclic compound in the preparation of a drug for treating and/or preventing respiratory diseases; the heterocyclic compound is a substance X, a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof; the substance X is a compound as shown in formula I or a compound as shown in formula II; the heterocyclic compound of the present invention has a good cough relieving effect.

Abstract: A salt of a ROCK inhibitor, a crystal form of the salt, a composition, and a pharmaceutical use are provided. The salt and the crystal form of the salt are an acid addition salt of a compound I and any acid in the following and a crystal form thereof: hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, benzenesulfonic acid, maleic acid, tartaric acid, oxalic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, camphorsulfonic acid, and 1, 5-naphthalene disulfonic acid. A free alkali crystal form of the compound I, the salt, and the crystal form of the salt have stable physical and chemical properties.

Abstract: This application provides an optical transmission device, a service device, and a service transmission method and system. The optical transmission device includes a first transceiver, an optical transceiver module, and a processor. The first transceiver is configured to receive a service packet from a switch. The optical transceiver module is configured to send the service packet to a target optical transmission device. The processor is configured to obtain status information of an optical transmission path for transmitting the service packet, and send the status information of the optical transmission path to the service device. The service device is configured to generate the service packet.

Abstract: An application of potassium ion (K+) channel blocker in preparation of drugs for treating liver fibrosis is provided, which relates to the field of medical technologies. The K+ channel blocker is sotalol, the sotalol is originally used as an antiarrhythmic drug in clinic and has a property of inhibiting K+ channels. Experiments show that sotalol can effectively inhibit liver fibrosis and reduce expression of fibrosis-related protein alpha-smooth muscle actin (?-SMA), specifically by regulating expression and/or function of autophagy and epithelial-mesenchymal transition (EMT) molecules to achieve inhibition of hepatic stellate cell (HSC) fibrosis, so as to provide a new drug choice for clinical treatment of the liver fibrosis.

Abstract: An application of a channel blocker in preparation of drugs for treating and/or preventing liver fibrosis is provided, belonging to the field of biomedical technology. A new use of phenytoin sodium is provided. It is demonstrated that at the cell level, the phenytoin sodium can improve liver fibrosis by regulating autophagy and thus affecting the activation of hepatic stellate cells. In this situation, the efficacy of the phenytoin sodium on liver fibrosis is verified at the animal level by establishing a disease model, and the phenytoin sodium can be used to prepare drugs for treating and/or preventing liver fibrosis.

Abstract: An ion channel blocker for treatment and/or prevention of hepatic fibrosis is provided. Based on the fact that the activation of hepatic stellate cells is an important link in anti-hepatic fibrosis, it is found that gliclazide has the effect of inhibiting the activation of hepatic stellate cells by in vitro and in vivo experiments. Further exploration reveals that gliclazide mainly inhibits the activation of hepatic stellate cells by inhibiting autophagy pathways, and thus the gliclazide can be used to prepare medicaments for treatment and/or prevention of hepatic fibrosis.

Abstract: Disclosed are a compound as an inhibitor of complement factor D, and a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereof and a prodrug thereof, or a pharmaceutically acceptable salt of any one of the above-mentioned compounds, or a solvate of any one of the above-mentioned compounds. The compound has a good inhibitory activity on complement factor D, and has an excellent pharmacokinetic and pharmacodynamic activity.

Abstract: Disclosed are a heterocyclic compound, and an intermediate thereof, a preparation method therefor and the use thereof. Namely, provided are a heterocyclic compound as shown in formula I-a, and a tautomer and a pharmaceutically acceptable salt thereof, wherein the compound has a good water solubility and pharmacokinetic properties.

Abstract: Disclosed in the present invention are a pharmaceutical composition, a preparation, and a preparation method therefor and the use thereof. The pharmaceutical composition contains an active ingredient and a pharmaceutically acceptable excipient. The active ingredient contains a compound represented by formula A. The compound represented by formula A is selected from one, two or more of the crystal form I, the crystal form III and the crystal form V. The excipient is selected-from or comprises, but is not limited to, one, two or more of the following excipients: a diluent, a disintegrant, an adhesive, a glidant and a lubricant. The pharmaceutical composition and the preparation of the present invention have a good safety and/or stability, and a high P2X3 antagonistic activity, and have less effect on the taste.

Abstract: An acid addition salt of a ROCK inhibitor, and a crystal form, a composition and the pharmaceutical use thereof are provided. The acid addition salt is an acid addition salt of compound A and any one of the following acids: hydrochloric acid, p-toluenesulfonic acid, benzenesulfonic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, sulfuric acid, methanesulfonic acid, phosphoric acid, succinic acid or citric acid (A). The acid addition salt of compound A and the crystal form thereof have the characteristics of high solubility, good stability, high purity, few impurities and high bioequivalence, and are beneficial for the storage, quality control and druggability of drugs.

Abstract: Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: Provided are a crystalline form of a compound represented by formula A, the crystalline form being crystalline form I, crystalline form II, crystalline form III, crystalline form IV, crystalline form V, crystalline form VI, crystalline form VII, crystalline form VIII or crystalline form IX, a preparation method therefor, a composition thereof, and an application thereof in the preparation of a P2X3 receptor antagonist or an application thereof in the preparation of drugs preventing and/or treating pains, urinary tract illness or respiratory system illness. The compound has high P2X3 antagonist activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: A ROCK inhibitor represented by formula (I), and a preparation method therefor and a use thereof are provided. The ROCK inhibitor has excellent ROCK inhibition activity, particularly shows good selective inhibition on ROCK2 kinase, has good safety and metabolic stability, and is high in bioavailability. The preparation method for the ROCK inhibitor is simple, and the ROCK inhibitor is easy to purify, and therefore has a good application prospect.

Abstract: Disclosed is a heterocyclic compound as represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof. The compound has better inhibitory activity on TRPC5, has good metabolic stability in liver micro-particles, and has good clinical pharmacokinetic properties.

Abstract: Compositions and methods to 3D print high quality inorganic nanostructures from a nanocomposite ink using two-photon polymerization are provided. Methods provide capability for 3D printing inorganic silica structures with sub-200 nm resolution with controlled crystallinity and doping. The final 3D printed inorganic product is shown to be pure SiO2, which can be in either glass or crystalline polymorph depending on the sintering process. The 3D printed fabricated products also show remarkable optical performance with the 3D printed micro-toroid optical resonators having quality factors (Q) over 104. For optical applications, doping and co-doping of rare earth salts such as Er3+, Tm3+, Yb3+, Eu3+ and Nd3+ can be directly implemented in the printed SiO2 structures.

Abstract: A compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof are provided. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.

Abstract: A multifunctional sofa includes armrest assemblies and seat units. A middle armrest is arranged between the adjacent seat units, and a front end of the middle armrest is provided with a cupholder. An upper end surface of the cupholder is provided with a cup slot, and an outer cover is also provided outside the cupholder. The outer cover may rotate relative to the cupholder to allow the one cup slot to be unfolded or folded. A movable function rack capable of rotating outwards relative to the armrest assembly is arranged in each of armrest assemblies. The movable function rack is provided with a function table. In the hidden position, the movable function rack is entirely located in the accommodating groove. In the use position, the movable function rack rotates outwards from the accommodating groove to protrude from the armrest assembly, and the function table is exposed outside.

Abstract: Methods of making hexagonal boron nitride coatings upon stainless steel and other ferrous metal/alloy materials, compositions thereof, and methods of using same, such as in electrothermal membrane distillation systems using hexagonal boron nitride coated metal mesh.

Abstract: Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

Abstract: A compound of formula (I), and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof can be used as JNK inhibitors. A method for preparing the compound of formula (I) and a pharmaceutical composition comprising the compound of formula (I) are provided. The compound of formula (I) can be used for preparing drugs. The resulting drugs are used for treating diseases that can be treated by inhibiting JNK activity.